An Immunogram for an Individualized Assessment of the Antitumor Immune Response in Patients With Hepatocellular Carcinoma

Ying Hu 1, Huaibo Sun 2, Henghui Zhang 3* and Xianbo Wang 1*

1 Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China, 2 Genecast Precision Medicine Technology Institute, Genecast Biotechnology Co., Ltd., Beijing, China, 3 Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China

In clinical practice, the cancer-immunity cycle of an individual patient with hepatocellular carcinoma (HCC) must be described to support the clinical management of cancer. The present study explored the immunograms of patients with liver cancer based on liver RNA sequencing data to visually display the individualized cancer-immunity cycles. Two independent HCC cohorts [The Cancer Genome Atlas (TCGA) and Liver Cancer-RIKEN, Japan (LIRI-JP) HCC cohorts] with whole exome sequencing (WES) data, RNA sequencing data, and clinical data from TCGA and International Cancer Genome Consortium (ICGC) were enrolled in this study. This study constructed HCC immunograms of cancer immune cells to visually explore the anticancer immune responses of patients with HCC. The patterns of the HCC immunograms were categorized into two clusters: hot and cold HCC immunograms. Favorable overall survival (OS) and disease-free survival (DFS) were observed in the hot immunogram cluster in the TCGA cohort. The results for LIRI-JP cohort were similar to the TCGA cohort. The OS of patients with HCC presenting the hot immunogram was longer than patients with the cold immunogram in the LIRI-JP HCC cohort. Compared with cold immunograms, hot immunograms were characterized by higher levels of immune cell infiltration and stronger immune signatures, including cytolytic activity, IFN-γ signature, immunocostimulator, immunoinhibitor, chemokine, adhesion molecule, MHC I, MHC II, and non-class MHC levels. The main difference in molecular features between hot and cold immunograms was reflected in WNT-CTNNB1 alterations and copy number variant (CNV) and loss of heterozygosity (LOH) scores, which are the molecular features associated with resistance to immunotherapy and tumor escape. The immunogram patterns were distinct in terms of the different molecular features of HCC tumors. The HCC immunogram for the cancer-immune cycle was able to visualize the personalized antitumor immune response of patients with HCC, and the patterns of the HCC immunograms contributed to the clinical outcomes of patients, which may facilitate an individualized assessment of the antitumor immune response for optimal personalized immunotherapy.

Keywords: hepatocellular carcinoma, immunogram, cancer-immunity cycle, antitumor immune response, prognosis
INTRODUCTION

An extensive clinical study has shown that cancer immunotherapy is a key component of the clinical management of cancer (1–3). A comprehensive understanding of the cancer-immune system interaction is crucial for developing new drugs and clinical strategies. Daniel S. Chen and Ira Mellman proposed the cancer-immunity cycle to illustrate the steps of the antitumor immune response, including the release of cancer cell antigens, cancer antigen presentation, priming, and activation, trafficking of T cells to tumors, infiltration of T cells into tumors, recognition of cancer cells by T cells, and killing of cancer cells, and to obtain a better understanding of the interactions between cancer and the immune system (4). From the perspective of the cancer-immunity cycles, cancer immunotherapy mainly includes two classes as described below. One class of immunotherapy is designed to improve the stimulatory immune factors, such as adoptive T cell therapy, which may lead the revolution of the cancer immunity cycle and potentially enhances the eventual self-propagation of the cycle (4). The other class of immunotherapy is designed to prevent immune effector inhibition, such as PD-1/PD-L1 blockade, which reinvigorates and potentially expands the pre-existing anticancer immune response (4, 5).

As described above, different immunotherapies are designed to regulate distinct dimensions of the cancer-immunity cycle.

Abbreviations: HCC, hepatocellular carcinoma; DFS, disease-free survival; OS, overall survival; CNV, copy number variant; LOH, loss of heterozygosity; TMB, tumor mutation burden; TCGA, The Cancer Genome Atlas.

Therefore, an evaluation of the cancer-immunity cycle of individual patients is the basis for implementing clinical strategies tailored to each patient. Based on the theory of the cancer-immunity cycle, Jun Nakajima constructed an immunogram that visually illustrates the cancer-immunity cycle of individual patients with lung cancer (6). The immunogram for the cancer-immunity cycle integrated all exam and RNA sequencing data, followed by the cloud transformation of the complex omics data in a radar plot to display the immune response of each patient. The steps of the cancer-immunity cycle were assessed using eight axes of the immunogram score (IGS), which included T cell immunity (IGS1), tumor antigenicity (IGS2), priming and activation (IGS3), trafficking and infiltration (IGS4), recognition of tumor cells (IGS5), inhibitor cells (IGS6), checkpoint expression (IGS7), and inhibitory molecules (IGS8). The immunogram will assist clinicians in making personalized medical decisions for each patient.

The liver is an immunological organ that contains numerous adaptive and innate immune cells (7). The liver is also a special anatomical organ in which the antigen-rich blood is scanned by antigen-presenting cells and lymphocytes through a network of sinusoids (8). Additionally, major hepatocellular carcinoma (HCC) occurs in patients with underlying chronic liver inflammation associated with hepatitis B or C virus infections, alcohol abuse, and fatty liver (9). Therefore, the immune microenvironment plays a vital role in HCC development. Previous studies illustrated the immune landscape of liver cancer based on single-cell data, RNA sequencing data, and T cell receptor sequence data (10).

---

**Flowchart of data collection and analysis**

![Flowchart of data collection and analysis](https://via.placeholder.com/150)

**FIGURE 1** Flowchart of the data collection and analysis process. The design of the study and the process of data selection are shown. Two independent HCC cohorts (TCGA and LIRI-JP HCC cohorts) with WES data, RNA sequencing data, and clinical data from TCGA and ICGC were enrolled in this study.
In clinical practice, the cancer-immunity cycle of individual patients with HCC must be described to support the clinical management of cancer. However, few studies have been published in this field. The present study explored immunograms of patients with HCC based on liver RNA-Seq data to visually display the personal cancer-immunity cycle. Moreover, we investigated the HCC immunogram and clinical outcomes and the correlation between the HCC immunogram and molecular features to better understand the individual anticancer immune response in the liver and support personal clinical decision making.

**MATERIALS AND METHODS**

**HCC Cohort and Data Collection and Preprocessing**

The design of the study and the process of data selection are shown in [Figure 1](#). We searched for HCC cohorts with whole exome sequencing (WES), RNA sequencing, and clinical data from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC). LIHC-TCGA and LIRI-JP HCC cohorts were enrolled in this study.

LIHC-TCGA was selected to explore the relations of the HCC immunogram and clinical outcomes, and LIRI-JP HCC was selected as an independent cohort to validate the prognostic value of the HCC immunogram. Data from the LIHC-TCGA and LIRI-JP HCC cohorts were downloaded from the UCSC Xena browser. The values of the RNA sequencing data (FPKM) were transformed into transcripts per million kilobase (TPM) values. The clinical information for the HCC cohort is shown in [Table 1](#).

**The HCC Immunogram**

According to a previous study, the steps of the cancer-immunity cycle are described by eight axes of the immunogram score (IGS) as follows: IGS1, T cell immunity; IGS2, tumor antigenicity; IGS3, priming and activation; IGS4, trafficking and infiltration; IGS5, recognition of tumor cells; IGS6, inhibitor cells; IGS7, checkpoint expression; and IGS8, inhibitory molecules (6). The gene sets IGS1, IGS3, IGS4, IGS5, IGS6, IGS7, and IGS8 were used in a previous study (6). A Gene Set Variation Analysis (GSVA) was performed to assess the value of IGS using GSVA R packages. The tumor neoantigenicity value was downloaded from published TCGA data (https://gdc.cancer.gov/about-data/publications/panimmune) (11). Unsupervised clustering of the IGS was performed using K-means clustering with the R package (version 3.6.1), as described in previous studies (12, 13). K-means clustering is one of the most commonly used unsupervised machine learning algorithms (13). The HCC immunograms were classified into two clusters. The two clusters of the immunograms in radar plots are shown as the median IGS.

**Immune-Related Gene Signature**

The gene sets for cytolytic activity (granzyme-A and perforin-1), the IFN-γ signature, immunocostimulators, immunoinhibitors, chemokines, HLA I signature, and HLA II signature were described in a previous study (14, 15). The immune signatures were measured as the geometric mean of gene expression in log2 of TPM+1.

**TABLE 1 | HCC immunogram cluster and clinical features.**

| Variable                        | Cold immunogram | Hot immunogram | P-value |
|---------------------------------|-----------------|----------------|---------|
| Age                             |                 |                | 0.320   |
| <60 years                       | 156             | 94             | 62      |
| ≥60 years                       | 180             | 98             | 82      |
| Gender                          |                 |                | 0.411   |
| Male                            | 228             | 126            | 102     |
| Female                          | 109             | 66             | 43      |
| Etiology                        |                 |                | 0.056   |
| Hepatitis B                     | 94              | 58             | 36      |
| Hepatitis C                     | 45              | 20             | 25      |
| Hepatitis B and C               | 6               | 1              | 5       |
| NAFLD                           | 15              | 8              | 7       |
| Alcohol consumption             | 66              | 34             | 32      |
| Vascular invasion               |                 |                | 0.589   |
| Micrvascular infiltration       | 81              | 50             | 31      |
| Macrovascular infiltration      | 14              | 7              | 7       |
| None                            | 188             | 105            | 83      |
| Unknown                         | 54              | 30             | 24      |
| Fibrosis                        |                 |                | 0.334   |
| No fibrosis                     | 66              | 43             | 23      |
| Portal fibrosis                 | 27              | 13             | 14      |
| Fibrous septa                   | 27              | 18             | 9       |
| Nodular formation               | 6               | 3              | 3       |
| Established cirrhosis           | 65              | 36             | 29      |
| Unknown                         | 146             | 79             | 67      |
| Stage                           |                 |                | 0.055   |
| I                               | 156             | 82             | 74      |
| II                              | 77              | 41             | 36      |
| III                             | 80              | 54             | 26      |
| IV                              | 5               | 3              | 2       |
| Child-pugh classification grade |                 |                | 0.611   |
| A                               | 199             | 117            | 82      |
| B                               | 19              | 13             | 6       |
| C                               | 1               | 0              | 1       |
| Unknown                         | 118             | 62             | 56      |
| Neoplasm histological type      |                 |                | 0.514   |
| Hepatocellular carcinoma        | 327             | 188            | 139     |
| Hepatocellular carcinoma        | 7               | 3              | 4       |
| Fibrolamellar carcinoma         | 3               | 1              | 2       |
| Neoplasm histological grade     |                 |                | 0.373   |
| G1                              | 48              | 29             | 19      |
| G2                              | 160             | 84             | 76      |
| G3                              | 113             | 70             | 43      |
| G4                              | 11              | 7              | 4       |
| Unknown                         | 5               | 2              | 3       |
FIGURE 2 | HCC cancer immunogram and prognosis. (A) Unsupervised clustering analysis of HCC immunograms based on eight axes of the IGS for 337 patients in the TCGA HCC cohort. The higher IGS cluster was termed the hot HCC immunogram, and the lower IGS cluster was termed the cold HCC immunogram. The clinical (Continued)
features, including age, sex, stage, fibrosis, etiology, histological type, and vascular invasion, are shown in patient annotations. (B) Kaplan–Meier curves for DFS of HCC patients in the TCGA cohort stratified into the two HCC immunogram clusters. The numbers of patients in the hot and cold immunogram clusters were 129 and 164, respectively. The log-rank test showed \( P = 0.00066 \). (C) Kaplan–Meier curves for OS of HCC patients in the TCGA cohort stratified into the two HCC immunogram clusters. The numbers of patients in the hot and cold immunogram clusters were 144 and 192, respectively. The log-rank test yielded \( P = 0.0057 \). (D) Kaplan–Meier curves for OS of HCC patients in the LIRI-JP HCC cohorts stratified into the two HCC immunogram clusters. The numbers of patients in the hot and cold immunogram clusters were 121 and 108, respectively. The log-rank test yielded \( P = 0.017 \). (E,F) The radar plot showed that the immunogram patterns of the two clusters were distinct. The axes of the radar chart were generated with the median IGS for the hot and cold immunogram clusters, respectively.

The heatmap of immune cell subsets that infiltrated the tumors of patients in the hot and cold HCC immunogram groups. The relative abundance of 28 immune cell subsets that infiltrated the tumor was evaluated with the sample level gene set enrichment method (GSVA) from the tumor RNA-Seq data. The clinical features, including age, sex, stage, fibrosis, etiology, histological type, and vascular invasion, are shown in the patient annotations.

Molecular Features
The tumor neoantigen burden, tumor mutation burden, CNV burden scores, and LOH scores were derived from published TCGA data (9). Somatic alterations in 10 oncogenic signaling pathways were analyzed as previously described (16). We grouped genes into known 10 canonical pathways that included the cell cycle, Hippo, Myc, Notch, Nrf2, PI3 kinase/Akt, RTK-RAS, TGFβ signaling, p53, and β-catenin/WNT, as previously described. The sample in which genes in specific pathways contained somatic mutations was designated as specific pathway altered. The sample in which all genes in specific pathways were wild type was designated as specific pathway unaltered. The difference in the cancer pathway alteration frequency between the two HCC immunogram clusters was assessed using Fisher’s exact test (two-sided).

Statistical Analysis
Data are presented as means and standard errors of the means (SEM). Group values were assessed using a normal distribution test. For normally distributed data, group means were compared using Student’s \( t \)-test, and non-parametric tests were performed when the data were not normally distributed. \( P < 0.05 \) was defined as statistically significant. Two-sided Fisher’s exact test was used to compare alteration frequencies between patients with
The immune signature strength of the hot and cold HCC immunogram groups. (A–H) The scatter plots showed higher levels of immune signatures, including cytolytic activity, cytolytic activity, IFN-γ signature, chemokine, immunoinhibitor, adhesion molecule, MHC I, MHC II, and non-class MHC, in hot HCC (Continued).
HCC presenting cold and hot HCC immunograms. The log-rank test was performed to investigate associations between the HCC immunogram patterns and the DFS and OS. Statistical analyses were performed using SPSS version 22.0 statistical software and R version 3.6.1.

RESULTS

HCC Cancer Immunogram and Prognosis

We adopted a cancer immunogram that visually illustrates the state of the cancer-immunity cycle to evaluate the antitumor response in patients with HCC. We explored the HCC immunogram of the TCGA cohort. Referring to a previous study, the steps of the cancer-immunity cycle are characterized by the following eight axes of the IGS: IGS1, T cell immunity; IGS2, tumor neoantigen burden; IGS3, priming and activation; IGS4, trafficking and infiltration; IGS5, recognition of tumor cells; IGS6, inhibitor cells; IGS7, checkpoint expression; and IGS8, inhibitor molecules. As shown in Figure 1, we collected the clinical data from the TCGA HCC cohort, WES, and RNA sequencing data. The landscape of the TCGA HCC cancer immunogram and the eight axes of the IGS are shown in Figure 2A. An unsupervised clustering analysis of the IGS was performed, and the HCC immunograms were separated into two clusters. The seven axes of the IGS of one cluster were significantly higher than the other cluster. The tumor neoantigen burden (IGS2) is not significantly changed between two clusters (Figure 2A and Supplementary Figure 1). The tumor neoantigen burden (IGS2) was not related to other axes of the immunogram, including T cell immunity (IGS1), priming and activation (IGS3), trafficking and infiltration (IGS4), recognition of tumor cells (IGS5), inhibitor cells (IGS6), checkpoint expression (IGS6), and inhibitor molecules (IGS8) (Supplementary Figure 2).

The cluster with higher immunogram scores was named the “hot immunogram,” and the cluster with lower immunogram scores was named the “cold immunogram.” Moreover, the two immunogram clusters of patients with HCC showed significant differences in DFS and OS (log-rank test, P < 0.01). Favorable OS and DFS were observed in patients with HCC and hot immunograms (Figures 2B,C). The radar plot showed that the immunogram patterns of the two clusters were distinct (Figures 2E,F). Furthermore, the relationship between clinical features and HCC immunogram patterns was investigated (Table 1). The immunogram patterns were not associated with clinical features, including age, gender, etiology, vascular invasion, fibrosis, stage, Child-Pugh classification grade, histological type, and neoplasm histological grade (Table 1).

The LIRI-JP HCC cohort was enrolled to test the HCC immunogram patterns and prognosis and to validate the prognostic value of the HCC immunograms. The clinical data, WES data, and RNA sequencing data were collected. HCC
TABLE 2 | HCC immunogram cluster and frequency of alterations in cancer-related pathways.

| Cancer pathway       | N   | Cold immunogram | Hot immunogram | P-value (Fisher’s Exact Test) |
|----------------------|-----|-----------------|----------------|-----------------------------|
| WNT pathway          |     |                 |                |                             |
| WNT altered          | 151 | 98              | 53             | 0.008                       |
| WNT unaltered        | 184 | 92              | 92             |                             |
| TGFβ pathway         |     |                 |                |                             |
| TGFβ altered         | 20  | 13              | 7              | 0.493                       |
| TGFβ unaltered       | 315 | 177             | 138            |                             |
| PI3K pathway         |     |                 |                |                             |
| PI3K altered         | 71  | 39              | 32             | 0.788                       |
| PI3K unaltered       | 264 | 151             | 113            |                             |
| RTK/RAS pathway      |     |                 |                |                             |
| RTK/RAS altered      | 115 | 69              | 46             | 0.417                       |
| RTK/RAS unaltered    | 220 | 121             | 99             |                             |
| Notch pathway        |     |                 |                |                             |
| Notch altered        | 77  | 47              | 30             | 0.432                       |
| Notch unaltered      | 258 | 143             | 115            |                             |
| Myc pathway          |     |                 |                |                             |
| Myc altered          | 14  | 11              | 3              | 0.105                       |
| Myc unaltered        | 321 | 179             | 142            |                             |
| Hippo pathway        |     |                 |                |                             |
| Hippo altered        | 108 | 63              | 45             | 0.724                       |
| Hippo unaltered      | 227 | 127             | 100            |                             |
| Nrf2 pathway         |     |                 |                |                             |
| Nrf2 altered         | 28  | 14              | 14             | 0.551                       |
| Nrf2 unaltered       | 307 | 176             | 131            |                             |
| Cell cycle pathway   |     |                 |                |                             |
| Cell cycle altered   | 44  | 29              | 15             | 0.197                       |
| Cell cycle unaltered | 291 | 161             | 130            |                             |
| P53 pathway          |     |                 |                |                             |
| P53 altered          | 127 | 79              | 48             | 0.139                       |
| P53 unaltered        | 208 | 111             | 97             |                             |

The bold values indicates P < 0.05.

immunograms of patients with HCC in the LIRI-JP cohort were assessed and an unsupervised clustering analysis of the IGS was performed using the methods mentioned above. The results for the LIRI-JP cohort were similar to the TCGA cohort. The HCC immunograms were separated into two clusters termed the “hot immunogram” and “cold immunogram” according to the IGS. The OS of patients with HCC presenting the hot immunogram was longer than that of patients with the cold immunogram (log-rank test, P < 0.01, Figure 2D).

The Immune Characteristics of Hot and Cold HCC Immunograms

The relative abundance of 28 immune cell subsets that infiltrate the tumor was evaluated using the single-sample Gene Set Enrichment Analysis (ssGSEA) method with the tumor RNA-Seq data. Immune cell infiltration was investigated in the two HCC immunogram clusters. As shown in Figure 3, greater numbers of 28 innate and adaptive immune cell subsets infiltrated the tumors of patients with hot immunograms than patients with cold immunograms. Furthermore, we observed higher levels of immune signatures, including cytolytic activity, IFN-γ signature, immunocostimulator, immunoinhibitor, chemokine, adhesion molecule, MHC I, MHC II, and non-class MHC, in hot HCC immunograms (P < 0.05, Figure 4).

The Molecular Features of Hot and Cold HCC Immunograms

The driver gene mutations and signaling pathway alterations between the two HCC cancer immunogram clusters were investigated. The WNT pathway was altered and the CTNNB1 gene mutation frequency was higher in the cold HCC immunogram cluster than in the hot HCC immunogram cluster (two-sided Fisher’s exact test, P < 0.05; Figure 5 and Table 2). The other signaling pathways, including the cell cycle, PI3K, P53, Notch, Myc, Hippo, Nrf2, and TGFβ pathways, were not significantly altered between the two HCC immunogram clusters (two-sided Fisher’s exact test, P > 0.05; Figure 5 and Table 2). Moreover, higher CNV burden scores and LOH scores were observed in the cold HCC immunogram cluster than in the hot HCC immunogram cluster (P < 0.05, Figure 6). The other genetic variants, including non-synonymous mutations, immunogenic mutations, indel numbers, and immunogenic indel numbers, were not significantly altered (P > 0.05, Figure 6).

The Immunogram Patterns of Molecular Features

The main differences in molecular features between hot and cold immunograms were reflected in WNT-CTNNB1 alterations and CNV and LOH scores. We further investigated the immunogram patterns of tumors with different molecular features. As shown in Figure 7, the immunogram patterns were distinct for different molecular features of HCC tumors. The radar plot revealed higher IGS for T cell immunity, inhibitor cells, and checkpoint expression in tumors without Wnt-CTNNB1 alterations than in tumors in which Wnt-CTNNB1 was altered (P < 0.05, Figure 5). Tumors with a high CNV burden were characterized by lower IGS for T cell immunity, priming and activation, trafficking and infiltration, recognition of tumor cells, inhibitor cells, checkpoint expression, and inhibitor molecules (P < 0.05, Figure 7B). Compared with tumors with a low LOH burden, tumors with a high LOH burden showed lower IGS for T cell immunity, priming and activation, trafficking and infiltration, and recognition of tumor cells and inhibitor molecules (P < 0.05, Figure 7C).

DISCUSSION

This study constructed an HCC immunogram of the cancer-immunity cycle to visually explore the anticancer immune responses of patients with HCC. The pattern of the HCC immunogram was categorized into two clusters, which were termed the hot immunogram and cold HCC immunogram. Favorable OS and DFS were observed for patients with HCC and
FIGURE 6 | The molecular features of hot and cold HCC immunograms. (A–F) Scatter plots show the levels of molecular features, including CNV burden scores, LOH scores, non-synonymous mutations, immunogenic mutations, indel numbers, and immunogenic indel numbers in the hot and cold HCC immunogram clusters, respectively. Group values were assessed using a normal distribution test. For normally distributed data, means of two clusters were compared using Student’s t-test, and non-parametric tests were performed when the data were not normally distributed (*P < 0.05, **P < 0.01, and ns: not significant, P > 0.05).
FIGURE 7 | The immunogram patterns of molecular features. (A–C) Radar charts showing the immunogram patterns in tumors with and without Wnt-CTNNB1 alterations (A), tumors with high and low CNV burdens (B), and tumors with high and low LOH scores (C). The median IGS are shown in the radar charts. Data were compared with non-parametric tests (*$P<0.05$).
hot immunograms. Moreover, the main difference in molecular features between hot and cold immunograms was reflected in WNT-CTNNB1 alterations and CNV and LOH scores. Meanwhile, the immunogram patterns were distinct for different molecular features of HCC tumors.

Based on emerging data, the anticancer immune response plays a vital role in cancer management (17–19). Previous studies reported an immunoscore based on an assessment of the numbers of CD3+ T cell and CD8+ T cells that infiltrated colon tumors (20). A recent study described three immunophenotypes based on CD8+ T cells, which included inflamed (CD8+ T cells infiltrated tumors, but were inhibited), immune excluded (CD8+ T cells accumulated, but had not efficiently infiltrated tumors), and immune desert (CD8+ T cells were absent from the tumor) (21). The immunophenotypes based on CD8+ T cells are helpful to understand the tumor microenvironment. Moreover, omics data from tumors provide additional information about the interaction of oncology and immunity. However, in clinical practice, clinicians must integrate data with multiple dimensions into a comprehensive visualization to assess the antitumor immune response and make appropriate clinical decisions for each patient. When the immunogram was utilized, the steps of the anticancer immune response of individual patients were described. In the present study, the different patterns of HCC immunograms were associated with different clinical outcomes. A significant benefit in terms of prognosis was observed in patients with HCC presenting hot immunograms. The results were validated in two independent HCC cohorts, including TCGA and LIRI-JP HCC cohorts. The antitumor response was likely activated in those patients, which reflected the higher IGS for T cell immunity, priming and activation, trafficking and infiltration, and recognition of tumor cells. In addition, greater numbers of infiltrated antitumor immune effector cells (activated CD8+ T cells and NK cells) and a stronger antitumor immune effector signature (cytolytic activity and IFN-γ) were associated with hot immunograms. Interestingly, the levels of immunoregulatory factors, including inhibitor cells, checkpoint expression, and inhibitor molecules, increased in patients with hot immunograms. We speculated that immunoregulatory factors exerted negative feedback on the activation of the antitumor immune response. The higher checkpoint expression associated with T cell-rich immunity and a strong immune effector signature (cytolytic activity and IFN-γ) may be related to the activation-exhaustion cascade in tumor-resident T cells (22).

The first step of the antitumor immune cycle is the release of tumor antigens and their capture by dendritic cells. Next, the dendritic cells present the captured antigens to T cells through MHCI and MHCII molecules, inducing the priming and activation of an effector T cell response against the cancer-specific antigens. However, the tumor neoantigen burden and tumor mutation burden of patients with HCC were not associated with T cell immunity, priming and activation, trafficking and infiltration, recognition of tumor cells, and antitumor immune effector signatures (cytolytic activity and IFN-γ). Our results were similar to the findings reported for patients with lung cancer (23). Based on these findings, progression from cancer neoantigen release to the T cell antitumor response involves multiple steps and complex mechanisms. As a single indicator, tumor neoantigens are unable to predict the antitumor immune response.

An understanding of the interaction between the tumor immune environment and molecular variations is vital to optimizing the immunotherapy strategy. In the present study, we investigated the alterations in 10 cancer-related pathways and molecular features between the two patterns of HCC immunograms. We observed a higher frequency of alterations in the WNT-CTNNB1 pathway in cold HCC immunogram pattern clusters. The immunogram patterns were distinct in tumors with and without WNT-CTNNB1 alterations. The radar plot showed higher IGS for T cell immunity, inhibitor cells, and checkpoint expression in tumors without Wnt-CTNNB1 alterations than in tumors with Wnt-CTNNB1 alterations. A clinical trial reported that patients with HCC carrying WNT/CTNNB1 mutations were resistant to immune checkpoint blockade (24). Our results may explain this immune resistance mechanism from the perspective of the HCC immunogram pattern. Moreover, our molecular analysis revealed higher CNV burden scores and LOH scores in the cold HCC immunogram cluster. The immunogram patterns of tumors with high CNV and LOH scores were characterized by lower IGS for T cell immunity, priming and activation, trafficking and infiltration, and recognition of tumor cells. A higher CNV and LOH burden in tumors correlated with immune escape and a poorer response to immunotherapy in previous studies (25, 26).

This study has several limitations. A further study should be designed to explore the clinical value of HCC immunograms in patient selection for personalized immunotherapy. From the perspective of theory, the individualized treatment strategies should be established based on the immunogram pattern for an assessment of the immune response of each patient.

In summary, a comprehensive understanding and assessment of the antitumor immune response is critical for medical decision making in cancer management. The present study used immunograms to provide visual antitumor immune response assessments for individual patients with HCC. Moreover, we illustrated the correlation between HCC immunograms and the molecular features of the tumor. This study may provide valuable resources for personalized HCC immunotherapy.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data can be found here: https://portal.gdc.cancer.gov/.

AUTHOR CONTRIBUTIONS

YH, HZ, and XW designed the study. YH and HS performed the data collection and analysis. YH explained the results and wrote the manuscript. All authors reviewed the manuscript.

FUNDING

This study was supported by the National Key Sci-Tech Special Project of China (No. 2018ZX10302207).
and the National Natural Science Foundation of China (No. 81774234).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.01189/full#supplementary-material

REFERENCES

1. Tang J, Yu JX, Hubbard-Lucey VM, Neifelín ST, Hodge JP, Lin Y. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. *Nat Rev Drug Discov.* (2018) 17:854–5. doi: 10.1038/nrd.2018.210
2. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science.* (2017) 357:409–13. doi: 10.1126/science.aan6733
3. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med.* (2020) 382:1894–905. doi: 10.1056/NEJMoa1915745
4. Chen DS, Mollman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity.* (2013) 39:1–10. doi: 10.1016/j.immuni.2013.07.012
5. Sannamede MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. *Cell.* (2018) 175:313–26. doi: 10.1016/j.cell.2018.09.035
6. Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, et al. An immunogram for the cancer-immunity cycle: towards personalised immunotherapy of lung cancer. *J Thorac Oncol.* (2017) 12:791–803. doi: 10.1016/j.jtho.2017.01.005
7. Racanelli V, Rehermann B. The liver as an immunological organ. *Hepatology.* (2006) 43(2 Suppl.1):S54–62. doi: 10.1002/hep.21060
8. Jenne CN, Kubes P. Immune surveillance by the liver. *Nat Immunol.* (2013) 14:996–1006. doi: 10.1038/ni.2691
9. Villanueva A. Hepatocellular carcinoma. *N Engl J Med.* (2019) 380:1450–62. doi: 10.1056/NEJMra1713263
10. Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, Guo X, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. *Cell.* (2017) 169:1342–56.e16. doi: 10.1016/j.cell.2017.05.035
11. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. *Immunity.* (2018) 48:812–30.e14. doi: 10.1016/j.immuni.2018.03.023
12. Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. *Cancer Immunol Res.* (2019) 7:737–50. doi: 10.1158/2326-6066.CIR-18-0436
13. Hartigan J, Wong MA. Algorithm AS 136: A K-means clustering algorithm. *Appl Statist R Statist Soc.* (1979) 28:100–8. doi: 10.2307/2346850
14. Ayers M, Luncerford J, Nebouzy M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma–related mRNA profile predicts clinical response to PD-1 blockade. *J Clin Invest.* (2017) 127:2930–40. doi: 10.1172/JCI91190
15. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype–immunophenotype relationships and predictors of response to checkpoint blockade. *Cell Rep.* (2017) 18:248–62. doi: 10.1016/j.celrep.2016.12.019

Supplementary Figure 1 | The boxplot shows the IGS of the hot and cold HCC immunogram clusters. Group values were assessed using a normal distribution test. For normally distributed data, mean values of the two clusters were compared using Student’s t-test; and non-parametric tests were performed when the data were not normally distributed (*P < 0.05, **P < 0.01, and ns: not significant, P > 0.05).

Supplementary Figure 2 | The correlation of eight axes of the IGS in the HCC immunogram.

16. Sanchez-Vega F, Mina M, Armenis J, Chatilla WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. *Cell.* (2018) 173:321–37.e10. doi: 10.1016/j.cell.2018.03.035
17. Chen DS, Mollman I. Elements of cancer immunoediting and the cancer-immune set point. *Nature.* (2017) 541:321–30. doi: 10.1038/nature21349
18. O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. *Nat Rev Clin Oncol.* (2019) 16:151–67. doi: 10.1038/s41571-018-0142-8
19. Galluzzi L, Chauon T, Kroemer G, Wolfe CK, Lopez-Soto A. The hallmarks of successful antitumor immunotherapy. *Sci Transl Med.* (2018) 10:eaat7807. doi: 10.1126/scitranslmed.aat7807
20. Pages E, Mlecnik B, Marliot F, Bifulco C, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet.* (2018) 391:2128–39. doi: 10.1016/S0140-6736(18)30789-X
21. Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. *Immunity.* (2020) 52:17–35. doi: 10.1016/j.immuni.2019.12.011
22. Blank CU, Haanen JB, Ribas A, Schumacher TN. Cancer immunology, “cancer immunogram.” *Science.* (2016) 352:658–60. doi: 10.1126/science.aaf2834
23. Jia Q, Wu W, Wang Y, Alexander PB, Sun C, Gong Z, et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. *Nat Commun.* (2018) 9:3361. doi: 10.1038/s41467-018-07767-w
24. Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. *Clin Cancer Res.* (2019) 25:2116–26. doi: 10.1158/1078-0432.CCR-18-2293
25. Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. *Science.* (2017) 355:eaaf8399. doi: 10.1126/science.aaf8399
26. McNamara N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. *Cell.* (2017) 171:1259–71.e11. doi: 10.1016/j.cell.2017.10.001

Conflict of Interest: HS was employed by the company Genecast Biotechnology Co., Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Hu, Sun, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.